- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - ...
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic ...
(RTTNews) - Johnson & Johnson MedTech, the medical technology arm of Johnson & Johnson (J&J) on Thursday said the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its ...
Subdural hematoma with mild symptoms progressed significantly less often when treated with middle meningeal artery (MMA) embolization compared with observation alone, new results from the second phase ...
SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) ...
Earlier this month, Medtronic received a new approval from the FDA for its decades-old liquid embolic system, extending its use to treat certain kinds of internal brain bleeds. Now, Johnson & Johnson ...
Johnson & Johnson and Viz.ai are pairing J&J’s neurovascular portfolio with Viz.ai’s FDA 510(k)-cleared Subdural Hemorrhage ...
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...